ACXP vs LEN · $11.3M cap vs rev $34.19B
Acurx Pharmaceuticals LLC (ACXP) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
Acurx Pharmaceuticals LLC (ACXP) is a biotechnology company listed on US.
LEN (LEN) common stock.
ACXP does not have a complete income-statement cache yet.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
ACXP currently screens at market cap $11.3M. LEN currently screens at market cap $0.
Not investment advice. Open the ACXP and LEN stock pages for the full models.
Not investment advice.